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Primary hepatic lymphoma (PHL) is an extremely rare disease, frequently associated with viruses such as hepatitis
B virus (HBV), hepatitis C virus (HCV), and human immune deficiency virus (HIV). On the other hand, an increased
risk of lymphoproliferative disorders (LPD) has been demonstrated in patients treated with immunosuppressive
drugs such as methotrexate (MTX) for rheumatoid arthritis (RA). The role of Epstein-Barr virus (EBV) has been
discussed in the pathogenesis of the immunodeficiency-associated LPDs. We here describe a RA patient, who
developed PHL during RA treatment. The patient was a 64 year-old Japanese male with a 2-year history of RA,
who had been treated with MTX at weekly dose of 8–14 mg for 2 years and infliximab (IFX) for 7 months. He presented
with a 2 month history of generalized malaise, right hypochondrium pain and fever. Contrast-enhanced computed
tomography (CECT) of the abdomen showed multiple irregular and nodular liver masses with a maximum of 13 cm in
diameter on the right liver. Biopsy specimens demonstrated CD20-positve diffuse large B-cell lymphoma (DLBCL), but
EBV was not identified by EBV-encoded RNA in situ hybridization. Serology for HBV, HCV, human T-cell leukemia virus I
(HTLV-I), and HIV was negative. His symptoms disappeared following discontinuation of RA treatment including MTX. A
drastic regression of the tumor masses was further obtained without cytotoxic chemotherapy. In addition, although the
patient had no past history of liver dysfunction before MTX therapy, persistent elevation of liver enzymes has been
observed during MTX treatment. These findings show a causative role of MTX in the development of reversible PHL in
the patient.
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Lymphoproliferative disorders (LPDs) developed in
autoimmune disease patients receiving immunosup-
pressive therapy are categorized as other iatrogenic
immunodeficiency-associated LPD in the WHO classi-
fication of tumors of hematopoietic and lymphoid
tissues [1]. The relationship between the development
of LPDs and immunosuppressive drugs, especially
methotrexate (MTX) for rheumatoid arthritis (RA) has
been discussed [2,3]. MTX has been the most widely
used as an anchor drug for the treatment of RA. The
advantages of anti-tumor necrosis factor (TNF) therapy
over MTX have been also recognized to reduce RA dis-
ease activity. However, it has been shown that the* Correspondence: jtsukada@med.uoeh-u.ac.jp
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unless otherwise stated.immunosuppressive state induced by these drugs pro-
vides a basis for the development of LPDs. Spontaneous
regression or disappearance of lymphoproliferative le-
sions after simple discontinuation of the immunosup-
pressive drugs further presents the evidence of
lymphomagenic potential of the immunosuppressive
drugs [3-7].
Immunodeficiency-associated LPDs, possess a wide
variety of spectrum with features, but share several clin-
ical characteristics, including frequent involvement of
extranodal lesions [5,8,9]. Here, we describe a RA pa-
tient treated with low dose MTX, who subsequently de-
veloped primary hepatic lymphoma (PHL).Case presentation
A 64-year-old man presented with a 2 month history of
generalized malaise, right hypochondrium pain and fever.ral. This is an Open Access article distributed under the terms of the Creative
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sarcoidosis and RA at the age of 62. He had been treated
with MTX at weekly dose of 8–14 mg for 2 years and
infliximab (IFX) at 3–6 mg/kg for 7 months for RA. Al-
though there has been no significant history of liver dys-
function before MTX therapy, persistent elevation of liver
enzymes has been observed during MTX treatment; aspar-
tate aminotransferase (AST) 36 to 128 U/L (normal value:
13–33) and alanine aminotransferase (ALT) 44 to 93 U/L
(normal value: 8–42). Physical examination at the time of
admission revealed neither enlarged superficial lymph
nodes nor jaundice. The laboratory findings on admission
were: white blood cell count 4.3X109/L, hemoglobin
11.1 g/dl, platelet count 147X109/L, AST 92 U/L, ALT 33
U/L, total bilirubin 1.1 mg/dl (normal value: 0.3-1.9), alka-
line phosphatase (ALP) 401 U/L (normal range 115–359)
and lactate dehydrogenase (LDH) 1,114 U/ml (normal
range 119–229). No lymphoma cells were detected in his
peripheral blood. A high LDH/AST ratio (12.1) was ob-
served. Soluble IL-2 receptor was 3,465 U/ml (normal
range 254–534). Serum carcinoembryonic antigen (CEA)
was within normal range, and alpha-fetoprotein (AFP) was
slightly elevated (16.3 ng/ml, normal value 10 ng/ml≧).
Serological tests for hepatitis B virus (HBV), hepatitis C
virus (HCV), human T-cell leukemia virus I (HTLV-I) and
human immune deficiency virus (HIV) were all negative.
Contrast-enhanced computed tomography (CECT) of
the abdomen (Figure 1A and B) revealed multiple irregu-
lar and nodular liver masses with a maximum of 13 cm
in diameter on the right liver. CECT scan of the brain,
neck, chest and pelvis showed no enlarged lymph nodes
or masses. Multiple hypoechoic bulky liver masses were
observed in ultrasound examination. There was no sig-
nificant bone marrow infiltration of lymphoma cells.Figure 1 Contrast-enhanced computed tomography (CECT) of the abdom
multiple liver masses.Diagnosis of PHL was made by using percutaneous
tumor biopsy of the liver, which had diffuse infiltration of
medium to large lymphoid cells with remarkable nucleoi.
The tumor cells were positive for CD20 (Figure 2B),
CD79a (Figure 2C) and CD10 (Figure 2D), and negative
for bcl-2 (Figure 2E), CD3 (Figure 2 F), and EBV-
encoded small RNAs (EBER) by in situ hybridization
(ISH) (Figure 2G). The findings were consistent with
non-Hodgkin lymphoma (NHL), diffuse large B-cell
lymphoma (DLBCL), and according to the WHO 2008
classification of lymphoid tissue, he was diagnosed as
other iatrogenic immunodeficiency-associated LPDs.
RA treatment including MTX was discontinued. He be-
came asymptomatic, and serum LDH returned to normal
levels. His liver function also improved. Oral prednisolone
(PSL) was administered at the initial dose of 60 mg/day
(0.7 mg/kg) for two weeks and was reduced to 10 mg/day
every three days. Three months after discontinuation of
RA treatment, the tumor masses dramatically regressed
(Figure 3). However, since a small liver mass was still
observed, the patient was further treated with a total of
8 cycles of R-CHOP: Rituximab (375 mg/m2) with cyclo-
phosphamide (750 mg/m2), vincristine (1.4 mg/m2), doxo-
rubicin (50 mg/m2) and prednisolone (60 mg/m2). There
has been no sign of recurrence for two years.
Discussion
PHL is extremely rare, representing 0.4% of extranodal
NHL [10] and 0.016-0.06% of NHL [11,12]. The most pre-
dominant type of PHL is DLBCL. The other histologic
types described in the literature include lymphoblastic
lymphoma, Burkitt lymphoma, anaplastic large cell lymph-
oma, follicular lymphoma and extranodal marginal zone
lymphoma of mucosa-associated lymphoid tissue, smallen at the time of admission (A) axial view; (B) coronal view showed
Figure 2 Histopathology of the liver tumor. (A) Hematoxylin and eosin (HE) staining, X400; (B) anti-CD20 staining, X400; (C) anti-CD79a staining,
X400; (D) anti-CD10 staining, X400; (E) anti-bcl-2 staining, X400; (F) anti-CD3 staining, X400; (G) EBV-encoded small RNAs (EBER) by in situ
hybridization (ISH), X400. Tumor cells are positive for CD20, CD79a and CD10 and negative for bcl-2, CD3 and EBER.
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ipheral T-cell lymphoma [13-15].
Clinical manifestations for PHL were non-specific.
Most of patients with PHL had abdominal pain, B-
symptoms and hepatomegaly associated with hepatic tu-
mors. PHL patients also have abnormal liver function
tests, mostly elevated AST and ALT. A solitary or mul-
tiple lesions in the liver was reported [11,14,16].The etiology of PHL still remains unclear, although vi-
ruses such as HBV, HCV, HIV and EBV have been impli-
cated as local factors in lymphomagenesis. A French
study of 31 patients with PHL including 22 patients of
primary hepatic DLBCL reported that the prevalence of
HCV and HBV infection was 21% and 9.5%, respectively
[15]. In a Japanese study of 20 patients with PHL, HCV
infection was observed in eight of 12 patients of primary
Figure 3 Three months after discontinuation of RA treatment, CECT
of the abdomen demonstrated a remarkable regression of the liver
masses.
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was 16.7% (2 of 12 primary hepatic DLBCL patients).
EBER was positive in two DLBCL PHL patients [17].
Thus, the two studies in France and Japan suggested a po-
tential pathogenic role of HCV infection in PHL develop-
ment. Persistent or chronic stimulation of the immune
system by HCV may result in clonal expansion of B-cells
in liver. HCV genome was detected in tumor cells of a pa-
tient with PHL [18]. In addition, the development of PHL
in HIV-positive patients has been also reported in the set-
ting of immunosuppressive states [19,20].
RA patients have a modestly increased risk of the de-
velopment of LPDs irrespective of immunosuppressive
therapy for the disease. In RA treatment, the most
popular immunosuppressive agent is MTX. Since the
first report of a RA patient by Ellman et al. [2], which
describes the development of lymphoma during low
dose weekly MTX therapy for 33 months, the develop-
ment of reversible LPDs has been recognized as a
complication of immunosuppression associated with
prolonged use of low dose MTX. Spontaneous regres-
sion of LPDs following discontinuation of MTX shows
the interplay of immunosuppression resulted from
MTX therapy with lymphoproliferation. Tumor cells of
the reversible LPDs frequently express EBV [3-7].
Approximately 40-50% of MTX-associated LPDs oc-
curred in extranodal sites [5,8,9]. Hoshida et al. reported
48 patients with MTX-associated LPDs, of whom the pri-
mary site was nodal in 22 patients, extranodal in 23 pa-
tients and undetermined in 3 patients [8]. A Study of 37
patients with MTX-associated LPDs reported extranodalorgan involvement, including lung, pleura, skin, salivary
glands, kidney and pancreas [5].
To our knowledge, four RA patients with MTX-
associated PHL have been reported in the English litera-
ture [17,21,22]. Among them, one patient reported by
Tatsumi et al. [21] was negative for HBV, HCV and HIV,
and tumor cells of the patient expressed EBER via ISH.
One patient reported by Miyagawa et al. [22] was nega-
tive for HBV, HCV and tumor cell EBER by ISH, but no
mention was made of HIV infection status. Moreover, it
is interesting to note that in contrast to our patient, the
two patients did not show spontaneous tumor regression
after the withdrawal of MTX. On the other hand, there
was no detailed description regarding the other two pa-
tients [17]. Our patient was negative for EBV, HBV,
HCV and HIV. MTX sometimes shows a significant hep-
atotoxicity. Persistent elevated transaminase levels were
noted while receiving MTX therapy in our patient. Based
upon the findings obtained from the present case, we
suggest the possibility that in addition to MTX-induced
immunosuppression, chronic liver injury resulted from
MTX may play a causative role in PHL development.
The fact that both of a drastic regression of the tumor
masses and improvement of liver dysfunction were ob-
served following discontinuation of MTX further sup-
ports our argument. However, because of the rarity of
PHL, further investigation should be required.Conclusion
PHL is a rare disease, frequently associated with viruses
such as HBV, HCV and HIV. Herein, we present the first
case of a reversible PHL occurred during RA treatment.
Symptoms of the patient disappeared following discon-
tinuation of RA treatment including MTX. A drastic re-
gression of the tumor masses was further obtained
without cytotoxic chemotherapy. The fact that persistent
elevations in liver enzymes have been observed during
MTX treatment also suggests a causative role of MTX in
the development of PHL in the patient.Consent
Written informed consent was obtained from the patient
for publication of the case report.Abbreviations
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